The expression level of MCT2 determines the [NOG]IC, which, at high levels, inhibits a number of low affinity metabolic targets such as GDH and IDH, leading to toxicity in MCT2-expressing cancer cells18. This evidence concerns the gene SLC16A7 and cancer.